Caution is advised when interpreting subgroup analyses

Klaus Munkholm^{1

2}, Asger Sand Paludan-Müller^{3

4}

Affiliations

¹ Centre for Evidence-Based Medicine Odense (CEBMO) and Cochrane Denmark, Department of Clinical Research, University of Southern Denmark, Odense, Denmark. kmunkholm@health.sdu.dk.
² Open Patient data Exploratory Network (OPEN), Odense University Hospital, Odense, Denmark. kmunkholm@health.sdu.dk.
³ Centre for Evidence-Based Medicine Odense (CEBMO) and Cochrane Denmark, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
⁴ Open Patient data Exploratory Network (OPEN), Odense University Hospital, Odense, Denmark.

Comment

Klaus Munkholm et al. Neuropsychopharmacology. 2021 Aug.

. 2021 Aug;46(9):1551.

doi: 10.1038/s41386-021-01025-2. Epub 2021 May 4.

Klaus Munkholm^{1

2}, Asger Sand Paludan-Müller^{3

4}

¹ Centre for Evidence-Based Medicine Odense (CEBMO) and Cochrane Denmark, Department of Clinical Research, University of Southern Denmark, Odense, Denmark. kmunkholm@health.sdu.dk.
² Open Patient data Exploratory Network (OPEN), Odense University Hospital, Odense, Denmark. kmunkholm@health.sdu.dk.
³ Centre for Evidence-Based Medicine Odense (CEBMO) and Cochrane Denmark, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
⁴ Open Patient data Exploratory Network (OPEN), Odense University Hospital, Odense, Denmark.

No abstract available

Comment in

Reply to Drs Munkholm and Paludan-Müller's comment on our paper "Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial".
Nettis MA, Pariante CM, Mondelli V. Nettis MA, et al. Neuropsychopharmacology. 2021 Aug;46(9):1552-1553. doi: 10.1038/s41386-021-01042-1. Epub 2021 May 26. Neuropsychopharmacology. 2021. PMID: 34040158 Free PMC article. No abstract available.

Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial.
Nettis MA, Lombardo G, Hastings C, Zajkowska Z, Mariani N, Nikkheslat N, Worrell C, Enache D, McLaughlin A, Kose M, Sforzini L, Bogdanova A, Cleare A, Young AH, Pariante CM, Mondelli V. Nettis MA, et al. Neuropsychopharmacology. 2021 Apr;46(5):939-948. doi: 10.1038/s41386-020-00948-6. Epub 2021 Jan 28. Neuropsychopharmacology. 2021. PMID: 33504955 Free PMC article. Clinical Trial.

1. Nettis MA, Lombardo G, Hastings C, Zajkowska Z, Mariani N, Nikkheslat N, et al. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial. Neuropsychopharmacology. 2021;46:939–48. - PMC - PubMed
1. Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ. 2010;340:c117. doi: 10.1136/bmj.c117. - DOI - PubMed
1. Sun X, Briel M, Busse JW, You JJ, Akl EA, Mejza F, et al. Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ. 2012;344:e1553. doi: 10.1136/bmj.e1553. - DOI - PubMed
1. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365:176–86. doi: 10.1016/S0140-6736(05)17709-5. - DOI - PubMed
1. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey, et al. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess. 2001;5:1–56. doi: 10.3310/hta5330. - DOI - PubMed